CHMP opinions for November include KRAS inhibitor sotorasib

CHMP has recommended approval of 11 new medicines and expanded labels for another seven drugs, including Amgen KRAS inhibitor sotorasib.

FDA approved Lumakras (Lumykras – EU) sotorasib in May, making it the first KRAS therapy to reach the market. On Nov. 2, Amgen reported the KRAS G12C inhibitor had brought in $45 million since its approval...